Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis

Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial.

A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. This study will test the efficacy and safety of ASF1057 in the treatment of patients with seborrhoeic dermatitis.

Inclusion Criteria:

• Clinical diagnosis of moderate to severe seborrhoeic dermatitis

Exclusion Criteria:

• Other active skin diseases
• Use of certain systemic and topical treatments
• Extensive sun exposure